Roche (OTC:RHHBY) said today that it won CE Mark clearance for its Accu-Chek Solo insulin micropump system.
The company plans to launch a pilot commercialization phase for its device in the coming weeks in Austria, Poland, Switzerland and the U.K.
Roche’s Accu-Chek Solo system features a small, tubeless insulin micropump and a remote control that incorporates blood glucose data and bolus advice, according to the company. The system is designed to give bolus insulin dosing from the remote control or directly from the pump.
The Accu-Chek Solo system also includes an option to detach and re-attach the pump without wasting insulin, Roche touted. It connects with digital solutions from Roche’s Diabetes Care business, including the Accu-Chek Smart Pix system.
“This important milestone will enable us to further expand access to insulin pump therapy to those people with diabetes who can benefit most from this therapy option – so they can spend more time in their ideal target range and experience an improved quality of life,” Roland Diggelmann, CEO of Roche Diagnostics, said in prepared remarks. “The new modular design of our Accu-Chek Solo micropump system responds to the needs of people with diabetes for more discretion and flexibility.”
